Illumina And Thermo Fisher Scientific Are The Leading Player In The Metagenomic Sequencing Market

By Author: Snehal S
Total Articles: 396
Comment this article

Growth in the metagenomic sequencing market is mainly driven by continuous technological innovations in NGS platforms, increasing initiatives and funding from government & private bodies for large-scale sequencing projects, declining costs of genome sequencing, and the significant applications of metagenomics in various fields.
The Metagenomic sequencing market is expected to reach USD 4.3 billion by 2027 from USD 1.9 billion in 2022, at a CAGR of 18.4% during the forecast period.

Download PDF Brochure :-https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=60408643

Illumina, Inc. (US), Thermo Fisher Scientific (US), QIAGEN N.V. (Netherlands), PerkinElmer, Inc. (US), and Oxford Nanopore Technologies Plc. (UK) are the prominent players operating in the metagenomic sequencing market.

Illumina (US) is the leading player in the metagenomic sequencing market, accounting for the largest share of the market in 2020. This is attributed to its robust product offerings and NGS services. The company’s product segment includes a wide range of sequencing, genotyping, gene expression, and molecular diagnostic ...
... platforms, consumables, and services that run on SBS technology. In the past three years, Illumina has launched several products in the market, including the NovaSeqT 6000 v1.5 Reagent Kit, TruSight Software Suite, NextSeq 1000, and NextSeq 2000. To ensure continuous product development, the company invests a significant amount of its revenue on R&D. It also focuses on agreements with leading players to co-develop advanced technologies and strengthen its research & commercialization capabilities. In the past three years, Illumina has entered into agreements with Helix OpCo, LLC (US), Roche (Switzerland), and QIAGEN (Netherlands).

Request Sample Pages: -https://www.marketsandmarkets.com/requestsampleNew.asp?id=60408643

Thermo Fisher Scientific (US) held the second position in the metagenomic sequencing market in 2020. The company’s NGS sequencers run on Ion Semiconductor sequencing technology. Thermo Fisher will continue to have a strong market position owing to its robust platforms and consumables offerings. The company also has a significant geographic presence. It adopts organic and inorganic strategies such as collaborations, partnerships, and product launches to strengthen its market position. For instance, in September 2021, it codeveloped NGS-based companion diagnostics with AstraZeneca.